Mankind Pharma Delivers Blockbuster Q3FY26: Revenue Tops ₹3,567 Cr, Profit at ₹409 Cr

Key Highlights

• Revenue Surge: Consolidated revenue from operations reached ₹35.67 billion (₹3,567 crore), fueled by 20%+ domestic growth in chronic segments and robust exports.
• Profit Strength: Net profit stood at ₹4.09 billion (₹409 crore), reflecting improved EBITDA margins from operational efficiencies and BSV consolidation.
• Domestic Dominance: Base business outperformance in anti-infectives, modern trade; chronic portfolio share expanded, OTC up 30% YoY.
• Strategic Wins: Exports soared 80%+, market share gains in top brands; R&D pipeline advances support long-term growth.

Forward View
With board approval on February 3, 2026, Mankind eyes sustained expansion via specialty drugs and digital health.

Sources: Univest.in, ScanX.Trade, CNBC TV18, Mankind Pharma Investor Relations.